RGEN: Repligen Corporation
RGEN exchange rate has changed by 0.63% for today. During the day, the instrument was traded at a low of 172.01 and at a high of 183.48.
Follow Repligen Corporation dynamics. Real-time quotes will help you quickly react to market changes. By switching between different timeframes, you can monitor exchange rate trends and dynamics by minutes, hours, days, weeks, and months. Use this information to forecast market changes and to make informed trading decisions.
- M5
- M15
- M30
- H1
- H4
- D1
- W1
- MN
RGEN News
- Canaccord Genuity Maintains Hold on Repligen, Raises Price Target to $180
- Repligen: A Buy As Its Growth Engine Gears Up (NASDAQ:RGEN)
- Barclays Maintains Overweight on Repligen, Raises Price Target to $225
- New Grades, Price Targets for the Top-3 Stocks in the Market’s Hottest Sector - TipRanks.com
- Merck's Remigromig Meets Main Goal in Diabetic Macular Edema Study
- AMGN's Dazodalibep Meets Goal in Systemic Sjogren's Disease Study
- Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290
- JNJ's Caplyta Shows Benefit in Bipolar 1 Related Mania Study
- 10 Health Care Stocks Whale Activity In Today’s Session
- NVS Gets Positive CHMP Opinion for Cosentyx for Another Indication
- Merck Gets CHMP Backing for Keytruda-Padcev Combo in Bladder Cancer
- CHMP Backs CORT's Lifyorli Combo in Platinum-Resistant Ovarian Cancer
- PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins
- RHHBY's Lunsumio Combo Meets Goal in 2L Follicular Lymphoma Study
- RCKT Aligns With FDA on Completing Phase II Study in Danon Disease
- Roche Gets FDA Priority Tag for Enspryng in Rare Autoimmune Disorder
- Novartis' Del-desiran Fails Late-Stage DM1 Study, Shares Fall
- FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug
- ABBV's Etentamig Meets Goals in Phase III Multiple Myeloma Study
- Software Rebound Extends Moat Index Gains
- Why Is ImmunityBio (IBRX) Up 9.7% Since Last Earnings Report?
- TEVA's TEV '408 Meets Goal in Phase IIa Celiac Disease Study
- QURE Submits Application for Gene Therapy for Huntington's Disease
- Novartis' Remibrutinib Delivers Positive Results in Late-Stage MS Studies
Frequently Asked Questions
What is RGEN stock price today?
Repligen Corporation stock is priced at 180.01 today. It trades within 172.01 - 183.48, yesterday's close was 178.88, and trading volume reached 2059. The live price chart of RGEN shows these updates.
Does Repligen Corporation stock pay dividends?
Repligen Corporation is currently valued at 180.01. Dividend policy depends on the company, while investors also watch 22.02% and USD. View the chart live to track RGEN movements.
How to buy RGEN stock?
You can buy Repligen Corporation shares at the current price of 180.01. Orders are usually placed near 180.01 or 180.31, while 2059 and 3.23% show market activity. Follow RGEN updates on the live chart today.
How to invest into RGEN stock?
Investing in Repligen Corporation involves considering the yearly range 100.99 - 198.86 and current price 180.01. Many compare -6.30% and 51.57% before placing orders at 180.01 or 180.31. Explore the RGEN price chart live with daily changes.
What are Repligen Corporation stock highest prices?
The highest price of Repligen Corporation in the past year was 198.86. Within 100.99 - 198.86, the stock fluctuated notably, and comparing with 178.88 helps spot resistance levels. Track Repligen Corporation performance using the live chart.
What are Repligen Corporation stock lowest prices?
The lowest price of Repligen Corporation (RGEN) over the year was 100.99. Comparing it with the current 180.01 and 100.99 - 198.86 shows potential long-term entry points. Watch RGEN moves on the chart live for more details.
When did RGEN stock split?
Repligen Corporation has gone through stock splits historically. These changes are visible in , 178.88, and 22.02% after corporate actions.
- Previous Close
- 178.88
- Open
- 174.37
- Bid
- 180.01
- Ask
- 180.31
- Low
- 172.01
- High
- 183.48
- Volume
- 2.059 K
- Daily Change
- 0.63%
- Month Change
- -6.30%
- 6 Months Change
- 51.57%
- Year Change
- 22.02%
- Act
- Fcst
- 198 K
- Prev
- 199 K
- Act
- Fcst
- 1.723 M
- Prev
- 1.710 M
- Act
- Fcst
- 0.0%
- Prev
- -0.1%
- Act
- Fcst
- Prev
- 1.955%